Oxford Nanopore Technologies plc (LON:ONT)
London · Delayed Price · Currency is GBP · Price in GBX 112.10
-0.20 (-0.18%)
Jul 20, 2026, 2:00 PM GMT
LON:ONT Revenue
In the year 2025, Oxford Nanopore Technologies had annual revenue of 223.90M GBP with 22.22% growth. Oxford Nanopore Technologies had revenue of 118.30M in the half year ending December 31, 2025, with 41.40% growth.
Revenue
223.90M
Revenue Growth
+22.22%
P/S Ratio
4.89
Revenue / Employee
170.14K
Employees
1,316
Market Cap
1.10B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 223.90M | 40.70M | 22.22% |
| Dec 31, 2024 | 183.20M | 13.53M | 7.98% |
| Dec 31, 2023 | 169.67M | -28.94M | -14.57% |
| Dec 31, 2022 | 198.60M | 64.94M | 48.59% |
| Dec 31, 2021 | 133.66M | 19.80M | 17.39% |
| Dec 31, 2020 | 113.86M | 61.80M | 118.70% |
| Dec 31, 2019 | 52.06M | 19.54M | 60.08% |
| Dec 31, 2018 | 32.52M | 18.73M | 135.88% |
| Dec 31, 2017 | 13.79M | 9.26M | 204.42% |
| Dec 31, 2016 | 4.53M | 3.78M | 507.10% |
| Dec 31, 2015 | 746.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Jun 30, 2009 | 361.22K | - | - |
| Jun 30, 2008 | - | - | - |
| Jun 30, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.00M |
| Oxford Biomedica | 168.74M |
| hVIVO | 49.66M |
| Bioventix | 12.54M |
| Scancell Holdings | 4.71M |
| PureTech Health | 3.46M |
| 4basebio | 1.69M |
| Ondine Biomedical | 1.43M |
Oxford Nanopore Technologies News
- 7 days ago - UK Stock Market News: PageGroup, ME Group, Oxford Nanopore - The Armchair Trader
- 7 days ago - Oxford Nanopore Technologies Earnings release: H1 2026 - Filings
- 9 days ago - Oxford Nanopore price target lowered to 220 GBp from 240 GBp at Citi - TheFly
- 4 months ago - Oxford Nanopore price target raised to 172 GBp from 170 GBp at Barclays - TheFly
- 4 months ago - Oxford Nanopore price target lowered to 225 GBp from 300 GBp at RBC Capital - TheFly
- 4 months ago - Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan - Business Wire
- 4 months ago - Oxford Nanopore Technologies Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 4 months ago - ViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore Sequencing - Business Wire